Virpax Pharmaceuticals Inc News - VRPX | Aktien NASDAQ | ADVFN

Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

Virpax Pharmaceuticals Inc (VRPX)

0,6201

-0,0414

(-6,26%)

Geschlossen 13 November 10:00PM

Verzögert um 15 Minuten

0,6049

-0,0152

(-2,45%)

Nach Börsenschluss: 12:55AM

Verzögert um 15 Minuten

Professionelle Tools für Privatanleger.

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain...

Foren

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Virpax Pharmaceuticals

Bank of Montreal Capped ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen